Skip to main content


Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others

June 05, 2020

Michael Birrer, MD, PhD, director of the Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, discusses the latest PARP inhibitor indications for frontline maintenance in ovarian cancer, as well as the impending results of other PARP inhibitor studies in the ovarian space.

View the podcast transcript

Back to Top